192 related articles for article (PubMed ID: 21881824)
21. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα.
Tsuda K; Tanimoto T; Hayakawa K; Komatsu T
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442
[No Abstract] [Full Text] [Related]
22. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
[No Abstract] [Full Text] [Related]
23. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
24. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis.
McPherson T; Cowen EW; McBurney E; Klion AD
Br J Dermatol; 2006 Oct; 155(4):824-6. PubMed ID: 16965435
[TBL] [Abstract][Full Text] [Related]
25. PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.
Vigna E; Lucia E; Gentile M; Mazzone C; Bisconte MG; Gentile C; Armentano A; Ottaviani E; Rondoni M; Martinelli G; Morabito F
Cancer Chemother Pharmacol; 2008 Apr; 61(4):713-6. PubMed ID: 17549478
[TBL] [Abstract][Full Text] [Related]
26. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Seferyńska I; Raźny M; Rodzaj M; Żuk E; Kyrcz-Krzemień S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):967-9. PubMed ID: 21327932
[No Abstract] [Full Text] [Related]
27. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Metzgeroth G; Erben P; Martin H; Mousset S; Teichmann M; Walz C; Klippstein T; Hochhaus A; Cross NC; Hofmann WK; Reiter A
Leukemia; 2012 Jan; 26(1):162-4. PubMed ID: 21818111
[No Abstract] [Full Text] [Related]
28. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].
Qu SQ; Wang Y; Sun XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226
[No Abstract] [Full Text] [Related]
29. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
30. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
31. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
32. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
[No Abstract] [Full Text] [Related]
33. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
34. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
35. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
36. Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.
Selvi N; Kaymaz BT; Sahin HH; Pehlivan M; Aktan C; Dalmızrak A; Inalpolat E; Kosova B; Yılmaz M; Okan V; Saydam G
Mol Biol Rep; 2013 Feb; 40(2):1591-7. PubMed ID: 23076533
[TBL] [Abstract][Full Text] [Related]
37. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia.
Tanaka H; Iwato K; Asou H; Kimura A
Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942
[TBL] [Abstract][Full Text] [Related]
38. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
Breccia M; Cilloni D; Cannella L; Stefanizzi C; Tafuri A; Fama A; Santopietro M; Saglio G; Alimena G
Cancer Chemother Pharmacol; 2009 May; 63(6):1161-3. PubMed ID: 18989670
[TBL] [Abstract][Full Text] [Related]
39. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
[TBL] [Abstract][Full Text] [Related]
40. Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy.
Tanaka Y; Kurata M; Togami K; Fujita H; Watanabe N; Matsushita A; Maeda A; Nagai K; Sada A; Matsui T; Takahashi T
Int J Hematol; 2006 Feb; 83(2):152-5. PubMed ID: 16513534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]